论文部分内容阅读
目的探讨胸腺肽联合抗生素治疗老年慢性阻塞性肺疾病急性加重期(AECOPD)患者的临床效果。方法选取2013年3月至2014年2月沈阳红十字会医院收治的88例AECOPD患者作为研究对象,根据随机数字表法将其分成A组(46例)与B组(42例)。B组患者给予抗生素,A组患者在对照组基础上采用胸腺肽进行治疗,比较两组患者治疗前后肺功能、免疫功能、生命质量、住院时间及用药安全性。结果治疗后,A组患者第1秒钟用力呼气容积(FEV1)与第1秒钟用力呼气容积占预计值的百分比(FEV1%)均明显高于B组,差异均有统计学意义(均P<0.05);治疗后,A组患者的CD4+明显高于B组,且CD4+/CD8+明显低于B组,差异均有统计学意义(均P<0.05);A组患者住院时间为(13.2±2.5)d,明显短于B组的(19±4)d,差异有统计学意义(t=34.410,P<0.05)。结论应用胸腺肽联合抗生素治疗AECOPD患者,可明显提高患者生命质量,加快康复,改善肺功能与免疫功能。
Objective To investigate the clinical effect of thymosin combined with antibiotics in the treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Eighty-eight patients with AECOPD admitted to Shenyang Red Cross Hospital from March 2013 to February 2014 were selected as study subjects and divided into group A (n = 46) and group B (n = 42) according to the random number table method. Patients in group B were given antibiotics. Patients in group A were treated with thymosin on the basis of control group. The pulmonary function, immune function, quality of life, hospital stay and medication safety were compared between the two groups before and after treatment. Results After treatment, FEV1 and forced expiratory volume in 1 second (FEV1%) of group A were significantly higher than those of group B (both groups were statistically significant ( (All P <0.05). After treatment, CD4 + in group A was significantly higher than that in group B, and CD4 + / CD8 + was significantly lower than that in group B (all P <0.05) 13.2 ± 2.5) d, which was significantly shorter than that of group B (19 ± 4) d, the difference was statistically significant (t = 34.410, P <0.05). Conclusion Thymosin combined with antibiotics in patients with AECOPD can significantly improve patient quality of life, speed up rehabilitation, improve lung function and immune function.